Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and… Read more
Kyntra Bio, Inc. (KYNB) - Net Assets
Latest net assets as of September 2025: $17.48 Million USD
Based on the latest financial reports, Kyntra Bio, Inc. (KYNB) has net assets worth $17.48 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($137.01 Million) and total liabilities ($119.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $17.48 Million |
| % of Total Assets | 12.76% |
| Annual Growth Rate | N/A |
| 5-Year Change | -141.6% |
| 10-Year Change | -193.3% |
| Growth Volatility | 89.92 |
Kyntra Bio, Inc. - Net Assets Trend (2012–2024)
This chart illustrates how Kyntra Bio, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kyntra Bio, Inc. (2012–2024)
The table below shows the annual net assets of Kyntra Bio, Inc. from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-183.63 Million | -13.22% |
| 2023-12-31 | $-162.20 Million | -10859.39% |
| 2022-12-31 | $-1.48 Million | -100.65% |
| 2021-12-31 | $229.11 Million | -48.10% |
| 2020-12-31 | $441.45 Million | -17.55% |
| 2019-12-31 | $535.41 Million | +1.31% |
| 2018-12-31 | $528.47 Million | -9.27% |
| 2017-12-31 | $582.45 Million | +232.62% |
| 2016-12-31 | $175.11 Million | -11.03% |
| 2015-12-31 | $196.82 Million | -18.22% |
| 2014-12-31 | $240.68 Million | +123.67% |
| 2013-12-31 | $107.60 Million | -11.93% |
| 2012-12-31 | $122.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kyntra Bio, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 164166300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.01 Million | % |
| Other Comprehensive Income | $-5.73 Million | % |
| Other Components | $1.67 Billion | % |
| Total Equity | $-225.60 Million | 100.00% |
Kyntra Bio, Inc. Competitors by Market Cap
The table below lists competitors of Kyntra Bio, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Argentum Silver Corp
PINK:AGSVF
|
$70.25K |
|
INTL ZEOLITE
F:ZEON
|
$70.30K |
|
CYBERAGENT (CL2.SG)
STU:CL2
|
$70.33K |
|
Canadian Banc Corp
PINK:CNDCF
|
$70.36K |
|
RENT3F
SA:RENT3F
|
$70.24K |
|
BIOCRYST PHARM
MU:BO1
|
$70.21K |
|
A S CREATION TAP N - Dusseldorf Stock Exchang
DU:ACWN
|
$70.19K |
|
Syncona Limited
LSE:SYNC
|
$70.15K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kyntra Bio, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -204,166,000 to -225,601,999, a change of -21,435,999.
- Net loss of 47,579,000 reduced equity.
- Dividend payments of 2,230,000 reduced retained earnings.
- Other comprehensive income increased equity by 1,143,001.
- Other factors increased equity by 27,230,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-47.58 Million | -21.09% |
| Dividends Paid | $2.23 Million | -0.99% |
| Other Comprehensive Income | $1.14 Million | +0.51% |
| Other Changes | $27.23 Million | +12.07% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Kyntra Bio, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $7.17 | $7.37 | x |
| 2013-12-31 | $1.69 | $7.37 | x |
| 2014-12-31 | $3.85 | $7.37 | x |
| 2015-12-31 | $2.94 | $7.37 | x |
| 2016-12-31 | $2.48 | $7.37 | x |
| 2017-12-31 | $7.72 | $7.37 | x |
| 2018-12-31 | $6.06 | $7.37 | x |
| 2019-12-31 | $5.96 | $7.37 | x |
| 2020-12-31 | $4.70 | $7.37 | x |
| 2021-12-31 | $2.26 | $7.37 | x |
| 2022-12-31 | $-0.23 | $7.37 | x |
| 2023-12-31 | $-2.10 | $7.37 | x |
| 2024-12-31 | $-2.26 | $7.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kyntra Bio, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -160.63%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-31.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -34.47% | -49.40% | 0.25x | 2.81x | $-42.02 Million |
| 2013 | -18.74% | -14.63% | 0.34x | 3.72x | $-22.92 Million |
| 2014 | -26.88% | -43.24% | 0.28x | 2.18x | $-81.64 Million |
| 2015 | -48.31% | -47.44% | 0.38x | 2.65x | $-103.53 Million |
| 2016 | -39.58% | -34.35% | 0.38x | 3.01x | $-77.26 Million |
| 2017 | -22.41% | -100.43% | 0.14x | 1.60x | $-182.52 Million |
| 2018 | -16.97% | -40.58% | 0.24x | 1.73x | $-137.34 Million |
| 2019 | -14.91% | -30.00% | 0.30x | 1.66x | $-128.58 Million |
| 2020 | -44.84% | -107.36% | 0.21x | 1.96x | $-231.51 Million |
| 2021 | -138.67% | -123.25% | 0.30x | 3.70x | $-310.94 Million |
| 2022 | 0.00% | -208.66% | 0.23x | 0.00x | $-291.51 Million |
| 2023 | 0.00% | -607.29% | 0.11x | 0.00x | $-263.82 Million |
| 2024 | 0.00% | -160.63% | 0.14x | 0.00x | $-25.02 Million |
Industry Comparison
This section compares Kyntra Bio, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kyntra Bio, Inc. (KYNB) | $17.48 Million | -34.47% | 6.84x | $70.25K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |